Trial
NCT04325698
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Advanced Non-squamous NSCLC
Intervention
PF-06439535 (CN)
Why stopped
The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-01